Adjuvant-induced Arthritis Model (AIA)

Adjuvant-induced Arthritis

Complete Freund's adjuvant is used to initiate induction of arthritis. This model was the original model of RA, has been extensively used to preclinical screening of new anti-arthritis compounds and has successfully predicted activity and toxicity in multiple new therapeutics. After a single injection of the adjuvant, a rapid, reliable, robust and easily measureable polyarthritis develops. The joint pathology seen in AIA share the cartilage degradation, bone reportion and cellular influx seen in human RA. This model is also T cell and neutrophil dependant with no requirement for B cells. Cytokines of both the Th1 and Th17 phenotype (eg. IL-1, IL-6, IL-17A, IL-21) are believed to play a role in the joint pathology. As this model is generally less severe than the CIA and is transient (normally resolving after a month), lower doses of test compounds can be effective in this model. The pathology however is not limited to the extremeties as the spine, GI tract, skin and even the eyes can be affected.

 

The injection of CFA in the tail base results in a chronic arthritis involving multiple joints, promoting a widespread systemic disease that results in severe discomfort and distress. By administering the CFA intrarticular and periarticular into the joint, you achieve a less servere monoarthritis within a few days.
 

Study Details:

  • Type: Monoarthritis or Polyarthritis
  • Length: 10-28 days
  • Dosing Paradigms: Prophylactic or Therapeutic
  • Dosing routes: PO, IP, SC, IV, Infusion pump
  • Controls: Dexamethasone, Enbrel, Morphine
  • Assessments: Arthritis Score, Hind paw thickness, Body weight

 

Optional Assessments:

  • Pain assessments (Von Frey, Thermal)
  • Circulating or tissue level Biomarker analysis (protein or mRNA)
  • Histological/IHC assessment of joints
  • PK blood collections

 

SPECIES AVAILABLE:


  • rat AIA
  • pig AIA

 

Request Study Proposal

 

 


CONTACT US:

1-888-876-3246
+41-44 986-2628
email us